MARKET

FENC

FENC

Fennec Pharmaceuticals Inc
NASDAQ
6.67
+0.10
+1.52%
After Hours: 6.67 0 0.00% 16:05 03/19 EDT
OPEN
6.59
PREV CLOSE
6.57
HIGH
6.90
LOW
6.46
VOLUME
233.56K
TURNOVER
--
52 WEEK HIGH
11.49
52 WEEK LOW
3.960
MARKET CAP
182.04M
P/E (TTM)
-2565.3846
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FENC last week (0310-0314)?
Weekly Report · 2d ago
Fennec Pharmaceuticals Price Target Maintained With a $13.00/Share by HC Wainwright & Co.
Dow Jones · 03/11 11:02
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $13 Price Target
Benzinga · 03/11 10:52
Fennec Pharmaceuticals Reports Strong 2024 Sales Growth
TipRanks · 03/11 03:59
Fennec Pharmaceuticals Shares Down After 4Q Results
Dow Jones · 03/10 19:37
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
Benzinga · 03/10 16:59
BUZZ-U.S. STOCKS ON THE MOVE-Willis Lease Finance, CME Group
Reuters · 03/10 16:12
BUZZ-Fennec Pharma falls on surprise Q4 loss
Reuters · 03/10 15:13
More
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Webull offers Fennec Pharmaceuticals Inc stock information, including NASDAQ: FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.